Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2025 earnings at $0.00 EPS, FY2028 earnings at $0.15 EPS and FY2029 earnings at $0.38 EPS.

Several other brokerages have also recently issued reports on SGMO. Wells Fargo & Company reduced their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Jefferies Financial Group cut their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, December 31st. Finally, Truist Financial decreased their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Sangamo Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $5.17.

Sangamo Therapeutics Price Performance

SGMO stock opened at $0.70 on Monday. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.39. The company has a market capitalization of $157.00 million, a price-to-earnings ratio of -0.93 and a beta of 1.57.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. Sell-side analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors have recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics during the 4th quarter valued at about $28,000. XTX Topco Ltd grew its stake in shares of Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after buying an additional 272,123 shares during the last quarter. State Street Corp raised its holdings in shares of Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 145,400 shares during the period. Finally, Golden State Equity Partners lifted its stake in shares of Sangamo Therapeutics by 2,592.3% during the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 313,587 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.